Analyst Reco. InnovAge Holding Corp.

Equities

INNV

US45784A1043

Delayed Nasdaq Other stock markets 09:30:00 2024-05-03 EDT			5-day change	1st Jan Change
4.17 ^USD	+2.21%		+6.65%	-30.50%

04-24	InnovAge Holding Corp. Launches PACE Center in Los Angeles	CI
03-13	JPMorgan Adjusts Price Target on InnovAge to $6 From $7, Maintains Neutral Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JPMorgan Adjusts Price Target on InnovAge to $6 From $7, Maintains Neutral Rating	03-13	MT
Goldman Sachs Trims Price Target on InnovAge Holding to $7 From $8, Maintains Neutral Rating	02-08	MT
JPMorgan Adjusts InnovAge Price Target to $7 From $8, Maintains Neutral Rating	23-09-18	MT
MORNING BID AMERICAS-Risk and rates moving in tandem	23-09-12	RE
Goldman Sachs Adjusts Price Target on InnovAge Holding to $9 From $8, Maintains Neutral Rating	23-02-15	MT
JPMorgan Raises InnovAge Holding's Price Target to $8 From $5, Maintains Neutral Rating	23-02-08	MT
Goldman Sachs Adjusts InnovAge Holding's Price Target to $8 From $6, Keeps Neutral Rating	22-11-23	MT
Citigroup Adjusts Price Target on InnovAge Holding to $8 From $5, Maintains Neutral Rating	22-11-16	MT
Barclays Adjusts Price Target on InnovAge to $5 From $6, Keeps Equalweight Rating	22-09-15	MT
Baird Downgrades InnovAge to Neutral From Outperform, Adjusts Price Target to $5 From $6	22-05-16	MT
Piper Sandler Lwoers InnovAge Holding's Price Target to $3.90 From $5, Underweight Rating Kept	22-05-11	MT
Piper Sandler Downgrades InnovAge to Underweight From Neutral, Adjusts Price Target to $5 From $4	22-04-20	MT
Goldman Sachs Cuts InnovAge to Neutral From Buy, Price Target to $4 From $15	21-12-28	MT
JPMorgan Lowers Price Target for InnovAge Holding to $6 From $10, Maintains Neutral Rating	21-12-27	MT
Barclays Lowers InnovAge to Equalweight From Overweight, Price Target to $6.50 From $22	21-12-27	MT
Baird Adjusts Price Target on InnovAge Holding to $11 From $22, Maintains Outperform Rating	21-12-23	MT
Piper Sandler Downgrades InnovAge to Neutral From Overweight, Adjusts Price Target to $4 From $14	21-12-23	MT
JPMorgan Starts InnovAge at Neutral With $10 Price Target	21-12-17	MT
Piper Sandler Adjusts Price Target on InnovAge to $14 From $20, Reiterates Overweight Rating	21-11-10	MT
INNOVAGE : Citigroup Downgrades InnovAge Holding to Neutral From Buy	21-09-29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. InnovAge Holding Corp.

Equities

INNV

US45784A1043

Analyst Reco.

Filters